Xenetic Biosciences, Inc. (XBIO) stock
XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3064% below fair value
$1.61+0.12 (+8.05%)
Close on Nov 17, 2026Market cap $3.77MP/E –Yield –
Earnings
Xenetic Biosciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 12, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$700.00K
-30.0% on a year earlier
EPS, Q3 FY2026
$0.72
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Xenetic Biosciences's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 12, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 13, 2026before the open | $700.00K | -30.0% | $0.72 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 7, 2026before the open | $700.00K | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 13, 2026before the open | $800.00K | +33.3% | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 13, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 13, 2025before the open | $1.00M | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 13, 2025before the open | – | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 14, 2025before the open | $600.00K | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 19, 2025before the open | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 13, 2024before the open | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 14, 2024before the open | $700.00K | – | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 10, 2024before the open | – | – | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 22, 2024before the open | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 13, 2023before the open | $600.00K | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 11, 2023before the open | – | – | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 11, 2023during market hours | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 23, 2023before the open | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 12, 2022before the open | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 23, 2022before the open | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 12, 2021before the open | – | – | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 13, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 12, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 17, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 13, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 13, 2020before the open | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 14, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Xenetic Biosciences has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Xenetic Biosciences puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Xenetic Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Results
- Results
- Results
- Update
- Results
- News
- Results
- Results
- Results
- Results
- Update
See a number that looks wrong?